EP Patent

EP3687607A1 — Intranasal delivery devices

Assigned to Shin Nippon Biomedical Laboratories Ltd · Expires 2020-08-05 · 6y expired

What this patent protects

The present invention relates to devices for administering powder formulations and methods of making and using such devices.

USPTO Abstract

The present invention relates to devices for administering powder formulations and methods of making and using such devices.

Drugs covered by this patent

dihydroergotamine-mesylate (DIHYDROERGOTAMINE MESYLATE)

Patent Metadata

Patent number: EP3687607A1
Jurisdiction: EP
Classification: —
Expires: 2020-08-05
Drug substance claim: No
Drug product claim: No
Assignee: Shin Nippon Biomedical Laboratories Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.